Trade Mark Journal No.2024/030 26 July 2024

UK00004075814 15 July 2024 (5,40,44)

ABATA

Class 5: Pharmaceutical preparations for T Cell therapy; pharmaceutical preparations and vaccines for use in gene therapy and cell therapy; biological preparations for use in medical and clinical gene therapy and cell therapy; pharmaceutical products for the prevention and treatment of cancer; immunotherapy products, namely, pharmaceutical preparations for the treatment of cancer, autoimmune diseases, and immunological disorders; biological preparations for the treatment of cancer autoimmune diseases, and immunological disorders; chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of cancer, autoimmune diseases and immunological disorders; antibodies and libraries of antibodies for medical purposes, for treatment and/or diagnosis of cancer, autoimmune diseases and immunological disorders.
Class 40: Custom manufacture of therapeutic drugs, namely, custom manufacture of cell therapies and cancer therapies; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for health care, for the treatment of humans suffering from diseases treated by cell therapy or regenerative medicine products, particularly medicines for human purposes including medicines for experimental purposes, biological products for experimental purposes, preparations for cell therapy and medicines for innovative therapies.
Class 44: Providing information regarding the treatment and/or diagnosis of cancer, autoimmune diseases and immunological disorders by means of a website.

Abata Therapeutics, Inc.

Representative: Abion UK Limited